(±) -Enitociclib

(±) -Enitociclib ((±) -BAY-1251152) is the racemic mixture of Enitociclib. Enitociclib is a selective CDK9 inhibitor and apoptosis inducer. Enitociclib inhibits CDK9 activity and reduces the phosphorylation of Ser2 in the carboxyl-terminal domain (CTD) of RNA polymerase Pol II, thereby downregulating the transcription of key oncogenes such as MYC and MCL1. Enitociclib has anti-proliferative activity targeting MYC+ lymphoma and multiple myeloma (MM) cells, and has synergistic effects with Bortezomib (HY-10227) and Lenalidomide (HY-A0003), and can be used in the research of hematological malignancies[1][2].

Product Specifications

CAS Number

1610358-53-6

Product Name Alternative

(±) -BAY-1251152; (±) -VIP152

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; CDK; DNA/RNA Synthesis

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/racemic-enitociclib.html

Purity

99.87

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

N=S(CC1=CC(NC2=NC=C(F)C(C3=CC=C(F)C=C3OC)=C2)=NC=C1)(C)=O

Molecular Formula

C19H18F2N4O2S

Molecular Weight

404.43

Precautions

H302, H315, H319, H335

References & Citations

[1]Frigault MM, et al. Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription. Cancer Res Commun. 2023 Nov 9;3 (11) :2268-2279.|[2]Tran S, et al. Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma[J]. Blood Neoplasia, 2025, 2 (1) : 100050.